Meng Ju Wu
About Meng Ju Wu
Meng Ju Wu is an Affiliate Postdoctoral Scholar at Harvard Medical School and Massachusetts General Hospital, specializing in cancer biology and immuno-oncology. With a Ph.D. from Purdue University, Wu has contributed to significant advancements in cancer therapeutics, including the FDA approval of TIBSOVO.
Work at Broad Institute
Meng Ju Wu has been serving as an Affiliate Postdoctoral Scholar at the Broad Institute of MIT and Harvard since 2019. In this role, Wu has engaged in various research initiatives, particularly focusing on tumor biology and immuno-oncology. Wu has conducted in vitro and in vivo CRISPR screenings in preclinical tumor models, contributing to target identification and validation efforts within the Tumor Immunotherapy Discovery Engine. This position allows for collaboration with leading researchers and institutions, enhancing the understanding of cancer therapies.
Education and Expertise
Meng Ju Wu holds a Doctor of Philosophy (Ph.D.) in Cancer Biology from Purdue University, where studies were conducted from 2012 to 2017. Prior to this, Wu earned a Master of Science (M.S.) in Oral Biology and a Bachelor of Science (B.S.) in Life Science from National Yang Ming University. The educational background equips Wu with a strong foundation in cancer research methodologies, including RNA sequencing and tumor model development.
Background and Previous Positions
Before joining the Broad Institute, Meng Ju Wu worked as a Postdoctoral Research Fellow at Harvard Medical School and Massachusetts General Hospital from 2018 to 2022. Wu's experience includes a role as an American Cancer Society Postdoctoral Fellow during 2021-2022. Additionally, Wu was a Postdoctoral Researcher at Purdue University from 2017 to 2018 and served as a Graduate Research Assistant at both Purdue University and National Yang Ming University, accumulating extensive research experience in cancer biology.
Research Contributions and Collaborations
Meng Ju Wu has made significant contributions to cancer research, including involvement in the FDA approval process for TIBSOVO, a therapeutic for advanced cholangiocarcinoma, through collaboration with Agios and Servier Pharmaceuticals. Wu has also formed alliances with experts in proteomics and metabolomics to analyze research data, identifying potential therapeutic targets. The research includes developing genetically engineered mouse tumor models and conducting anti-tumor efficacy studies.
Grants and Funding
Meng Ju Wu has successfully secured grants from the National Institutes of Health (NIH) and established Scientific Research Agreements with industry leaders such as Agios Pharmaceuticals, Servier Pharmaceuticals, and AbbVie. These funding efforts support Wu's research initiatives and collaborations, facilitating advancements in cancer treatment and therapeutic development.